Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CoREST complex inhibition alters RNA splicing to promote neoantigen expression and enhance tumor immunity
Robert J. Fisher, Kihyun Park, Kwangwoon Lee, Katarina Pinjusic, Allison Vanasse, Christina S. Ennis, Parisa Farokh, Scott B. Ficaro, Jarrod A. Marto, Hanjie Jiang, Eunju Nam, Stephanie Stransky, Joseph Duke-Cohan, Melis A. Akinci, Anupa Geethadevi, Eric Raabe, Ana Fiszbein, Shadmehr Demehri, Simone Sidoli, Chad W. Hicks, Derin B. Keskin, Catherine J. Wu, Philip A. Cole, Rhoda M. Alani
Robert J. Fisher, Kihyun Park, Kwangwoon Lee, Katarina Pinjusic, Allison Vanasse, Christina S. Ennis, Parisa Farokh, Scott B. Ficaro, Jarrod A. Marto, Hanjie Jiang, Eunju Nam, Stephanie Stransky, Joseph Duke-Cohan, Melis A. Akinci, Anupa Geethadevi, Eric Raabe, Ana Fiszbein, Shadmehr Demehri, Simone Sidoli, Chad W. Hicks, Derin B. Keskin, Catherine J. Wu, Philip A. Cole, Rhoda M. Alani
View: Text | PDF
Research Article Dermatology Oncology Therapeutics

CoREST complex inhibition alters RNA splicing to promote neoantigen expression and enhance tumor immunity

  • Text
  • PDF
Abstract

Epigenetic macromolecular enzyme complexes tightly regulate gene expression at the chromatin level and have recently been found to colocalize with RNA splicing machinery during active transcription; however, the precise functional consequences of these interactions are uncertain. Here, we identify unique interactions of the CoREST repressor complex (LSD1-HDAC1-CoREST) with components of the RNA splicing machinery and their functional consequences in tumorigenesis. Using mass spectrometry, in vivo binding assays, and cryo-EM, we find that CoREST complex–splicing factor interactions are direct and perturbed by the CoREST complex selective inhibitor, corin, leading to extensive changes in RNA splicing in melanoma and other malignancies. Moreover, these corin-induced splicing changes are shown to promote global effects on oncogenic and survival-associated splice variants, leading to a tumor-suppressive phenotype. Using machine learning models, MHC IP-MS, and ELISpot assays, we identify thousands of neopeptides derived from unannotated splice sites that generate corin-induced splice-neoantigens that are demonstrated to be immunogenic in vitro. Corin is further shown to reactivate the response to immune checkpoint blockade, effectively sensitizing tumors to anti–PD-1 immunotherapy. These data position CoREST complex inhibition as a unique therapeutic opportunity that perturbs oncogenic splicing programs while also creating tumor-associated neoantigens that enhance the immunogenicity of current therapeutics.

Authors

Robert J. Fisher, Kihyun Park, Kwangwoon Lee, Katarina Pinjusic, Allison Vanasse, Christina S. Ennis, Parisa Farokh, Scott B. Ficaro, Jarrod A. Marto, Hanjie Jiang, Eunju Nam, Stephanie Stransky, Joseph Duke-Cohan, Melis A. Akinci, Anupa Geethadevi, Eric Raabe, Ana Fiszbein, Shadmehr Demehri, Simone Sidoli, Chad W. Hicks, Derin B. Keskin, Catherine J. Wu, Philip A. Cole, Rhoda M. Alani

×

Figure 8

Corin sensitizes immune cold tumors to immunotherapy and promotes expansion of tumor infiltrating cytotoxic T cells.

Options: View larger image (or click on image) Download as PowerPoint
Corin sensitizes immune cold tumors to immunotherapy and promotes expans...
(A) Schematic for corin + immunotherapy combination treatment in a melanoma xenograft mouse model. Six- to 10-week-old female C57BL/6 mice were inoculated with 2.5 × 105 B16-F10 cells. Mice were treated with 200 μg/mouse of corin or 200 μL vehicle control (5% DMSO/PBS) by daily i.p. injection starting from day 6 after tumor initiation. For anti–PD-1 treatment, mice were treated with 150 μg/mice anti–PD-1 or isotype control antibody 3 times/week starting from day 7 after tumor grafting. Ten mice were included in each treatment group. Tumors were measured 3 times/week and tumor volume, tumor weight, body weight change, spleen weight were measured. (B and C) Line plot and quantification of tumor volumes from day 7 to day 15 comparing DMSO, αPD-1, corin, and αPD-1 + corin treatment. (D) Histogram of tumor volumes depicted in B. (E) Histogram of body weight change relative to day 0 in animals treated with DMSO, αPD-1, corin, and αPD-1 + corin. (F) Histogram of spleen weights in animals treated with DMSO, αPD-1, corin, and αPD-1 + corin. Statistical analyses for C–F were performed using an ordinary 1-way ANOVA with Holm-Šídák’s correction for multiple comparisons. Data are shown as mean ± SD. (G) scRNA-Seq UMAP of the immune population (CD45+) isolated from B16-F10 melanomas. (H) Heatmap of the marker genes used to define immune subpopulations in G. (I) Subset UMAP of the T cell compartment comparing αPD-1 treatment to the combination of αPD-1 + corin. (J) Stacked bar plot of the T cell compartments in I. (K) Violin plots of significant DEGs (Log2FC > |1|, Padj < 0.05) in T cell populations isolated from αPD-1 versus αPD-1 + corin-treated B16-F10 melanomas. (L) GSEA plots for T cell populations isolated from αPD-1 versus αPD-1 + corin-treated B16-F10 melanomas showing enrichment for cytokine activity, leukocyte migration in inflammation, antigen response, and immune response in the αPD-1 + corin–treated tumors.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts